Ji Hyun Lee1, Jae Hui Kim2, Jong Woo Kim1, Chul Gu Kim1, Dong Won Lee1. 1. Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea. 2. Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea. kimoph@gmail.com.
Abstract
PURPOSE: To evaluate the difference in the treatment burden among different types of neovascular age-related macular degeneration (AMD). METHODS: This retrospective, observational study included 431 patients who were diagnosed with neovascular AMD. Patients were divided into three groups: type 1 or 2 neovascularization group (n = 167), type 3 neovascularization group (n = 50), and polypoidal choroidal vasculopathy (PCV) group (n = 214). The number of hospital visits per year and the number of anti-vascular endothelial growth factor (VEGF) injections per year were compared among these groups. Furthermore, the incidence of bilateral involvement during the follow-up period was compared among the groups. RESULTS: The mean follow-up period was 50.6 ± 11.3 months. The number of hospital visits per year was significantly higher in the type 1 or 2 neovascularization group (mean: 6.1 ± 1.5) and type 3 neovascularization (6.6 ± 1.6) than in the PCV group (6.0 ± 1.5) (P < 0.001). The number of anti-VEGF injections per year was significantly higher in type 3 neovascularization group (3.1 ± 1.7) than in the type 1 or 2 neovascularization group (2.3 ± 1.5) or the PCV group (2.3 ± 1.2) (P = 0.042). There was a significant difference in the incidence of bilateral involvement among patients in type 1 or 2 neovascularization group (20.4%), type 3 neovascularization group (46.0%), and the PCV group (15.4%) (P < 0.001). CONCLUSIONS: The high frequency of hospital visits and that of anti-VEGF injections in patients with type 3 neovascularization suggests high treatment burden in these patients. The high incidence of bilateral involvement could be one of the primary reasons for high treatment burden in patients with type 3 neovascularization.
PURPOSE: To evaluate the difference in the treatment burden among different types of neovascular age-related macular degeneration (AMD). METHODS: This retrospective, observational study included 431 patients who were diagnosed with neovascular AMD. Patients were divided into three groups: type 1 or 2 neovascularization group (n = 167), type 3 neovascularization group (n = 50), and polypoidal choroidal vasculopathy (PCV) group (n = 214). The number of hospital visits per year and the number of anti-vascular endothelial growth factor (VEGF) injections per year were compared among these groups. Furthermore, the incidence of bilateral involvement during the follow-up period was compared among the groups. RESULTS: The mean follow-up period was 50.6 ± 11.3 months. The number of hospital visits per year was significantly higher in the type 1 or 2 neovascularization group (mean: 6.1 ± 1.5) and type 3 neovascularization (6.6 ± 1.6) than in the PCV group (6.0 ± 1.5) (P < 0.001). The number of anti-VEGF injections per year was significantly higher in type 3 neovascularization group (3.1 ± 1.7) than in the type 1 or 2 neovascularization group (2.3 ± 1.5) or the PCV group (2.3 ± 1.2) (P = 0.042). There was a significant difference in the incidence of bilateral involvement among patients in type 1 or 2 neovascularization group (20.4%), type 3 neovascularization group (46.0%), and the PCV group (15.4%) (P < 0.001). CONCLUSIONS: The high frequency of hospital visits and that of anti-VEGF injections in patients with type 3 neovascularization suggests high treatment burden in these patients. The high incidence of bilateral involvement could be one of the primary reasons for high treatment burden in patients with type 3 neovascularization.
Authors: L A Yannuzzi; S Negrão; T Iida; C Carvalho; H Rodriguez-Coleman; J Slakter; K B Freund; J Sorenson; D Orlock; N Borodoker Journal: Retina Date: 2001 Impact factor: 4.256
Authors: S Y Cohen; C Creuzot-Garcher; J Darmon; T Desmettre; J F Korobelnik; F Levrat; G Quentel; S Paliès; A Sanchez; A Solesse de Gendre; H Schluep; M Weber; C Delcourt Journal: Br J Ophthalmol Date: 2007-03-23 Impact factor: 4.638
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Johanna M Colijn; Gabriëlle H S Buitendijk; Elena Prokofyeva; Dalila Alves; Maria L Cachulo; Anthony P Khawaja; Audrey Cougnard-Gregoire; Bénédicte M J Merle; Christina Korb; Maja G Erke; Alain Bron; Eleftherios Anastasopoulos; Magda A Meester-Smoor; Tatiana Segato; Stefano Piermarocchi; Paulus T V M de Jong; Johannes R Vingerling; Fotis Topouzis; Catherine Creuzot-Garcher; Geir Bertelsen; Norbert Pfeiffer; Astrid E Fletcher; Paul J Foster; Rufino Silva; Jean-François Korobelnik; Cécile Delcourt; Caroline C W Klaver Journal: Ophthalmology Date: 2017-07-14 Impact factor: 12.079